#BEGIN_DRUGCARD DB03127

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
618-39-3

# ChEBI_ID:
41033

# Chemical_Formula:
C7H9N2

# Chemical_IUPAC_Name:
[amino(phenyl)methylidene]azanium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Serine Proteinase Inhibitors

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Benzamidine

# HET_ID:
BAM

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C7H8N2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H3,8,9)/p+1

# InChI_Key:
InChIKey=PXXJHWLDUBFPOL-UHFFFAOYSA-O

# Indication:
Not Available

# KEGG_Compound_ID:
C01784

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3127

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
121.1598

# Molecular_Weight_Mono:
121.076573298

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1HJ8

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.8

# Predicted_LogS:
-1.6

# Predicted_Water_Solubility:
3.57e+00 g/l

# Primary_Accession_No:
DB03127

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
444655

# PubChem_Substance_ID:
46504844

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00669

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(=[NH2+])C1=CC=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:56 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
CSNK2A1

# Drug_Target_10_GenBank_ID_Gene:
J02853

# Drug_Target_10_GenBank_ID_Protein:
598147

# Drug_Target_10_GeneCard_ID:
CSNK2A1

# Drug_Target_10_Gene_Name:
CSNK2A1

# Drug_Target_10_Gene_Sequence:
>1176 bp
ATGTCGGGACCCGTGCCAAGCAGGGCCAGAGTTTACACAGATGTTAATACACACAGACCT
CGAGAATACTGGGATTACGAGTCACATGTGGTGGAATGGGGAAATCAAGATGACTACCAG
CTGGTTCGAAAATTAGGCCGAGGTAAATACAGTGAAGTATTTGAAGCCATCAACATCACA
AATAATGAAAAAGTTGTTGTTAAAATTCTCAAGCCAGTAAAAAAGAAGAAAATTAAGCGT
GAAATAAAGATTTTGGAGAATTTGAGAGGAGGTCCCAACATCATCACACTGGCAGACATT
GTAAAAGACCCTGTGTCACGAACCCCCGCCTTGGTTTTTGAACACGTAAACAACACAGAC
TTCAAGCAATTGTACCAGACGTTAACAGACTATGATATTCGATTTTACATGTATGAGATT
CTGAAGGCCCTGGATTATTGTCACAGCATGGGAATTATGCACAGAGATGTCAAGCCCCAT
AATGTCATGATTGATCATGAGCACAGAAAGCTACGACTAATAGACTGGGGTTTGGCTGAG
TTTTATCATCCTGGCCAAGAATATAATGTCCGAGTTGCTTCCCGATACTTCAAAGGTCCT
GAGCTACTTGTAGACTATCAGATGTACGATTATAGTTTGGATATGTGGAGTTTGGGTTGT
ATGCTGGCAAGTATGATCTTTCGGAAGGAGCCATTTTTCCATGGACATGACAATTATGAT
CAGTTGGTGAGGATAGCCAAGGTTCTGGGGACAGAAGATTTATATGACTATATTGACAAA
TACAACATTGAATTAGATCCACGTTTCAATGATATCTTGGGCAGACACTCTCGAAAGCGA
TGGGAACGCTTTGTCCACAGTGAAAATCAGCACCTTGTCAGCCCTGAGGCCTTGGATTTC
CTGGACAAACTGCTGCGATATGACCACCAGTCACGGCTTACTGCAAGAGAGGCAATGGAG
CACCCCTATTTCTACACTGTTGTGAAGGACCAGGCTCGAATGGGTTCATCTAGCATGCCA
GGGGGCAGTACGCCCGTCAGCAGCGCCAATATGATGTCAGGGATTTCTTCAGTGCCAACC
CCTTCACCCCTTGGACCTCTGGCAGGCTCACCAGTGATTGCTGCTGCCAACCCCCTTGGG
ATGCCTGTTCCAGCTGCCGCTGGCGCTCAGCAGTAA

# Drug_Target_10_General_Function:
Involved in protein kinase activity

# Drug_Target_10_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
2174700	Lozeman FJ, Litchfield DW, Piening C, Takio K, Walsh KA, Krebs EG: Isolation and characterization of human cDNA clones encoding the alpha and the alpha' subunits of casein kinase II. Biochemistry. 1990 Sep 11;29(36):8436-47.
2752008	Meisner H, Heller-Harrison R, Buxton J, Czech MP: Molecular cloning of the human casein kinase II alpha subunit. Biochemistry. 1989 May 2;28(9):4072-6.
8420794	Devilat I, Carvallo P: Structure and sequence of an intronless gene for human casein kinase II-alpha subunit. FEBS Lett. 1993 Jan 25;316(2):114-8.

# Drug_Target_10_HGNC_ID:
HGNC:2457

# Drug_Target_10_HPRD_ID:
00277

# Drug_Target_10_ID:
2236

# Drug_Target_10_Locus:
20p13

# Drug_Target_10_Molecular_Weight:
45144

# Drug_Target_10_Name:
Casein kinase II subunit alpha

# Drug_Target_10_Number_of_Residues:
391

# Drug_Target_10_PDB_ID:
1JWH

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_10_Protein_Sequence:
>Casein kinase II subunit alpha
MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINIT
NNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTD
FKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAE
FYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYD
QLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDF
LDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSMPGGSTPVSSANMMSGISSVPT
PSPLGPLAGSPVIAAANPLGMPVPAAAGAQQ

# Drug_Target_10_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. The alpha and alpha' chains contain the catalytic site. Participates in Wnt signaling. CK2 phosphorylates 'Ser-392' of p53/TP53 following UV irradiation

# Drug_Target_10_SwissProt_ID:
P68400

# Drug_Target_10_SwissProt_Name:
CSK21_HUMAN

# Drug_Target_10_Synonyms:
CK II
EC 2.7.11.1

# Drug_Target_10_Theoretical_pI:
7.86

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
KLK6

# Drug_Target_1_GenBank_ID_Gene:
U62801

# Drug_Target_1_GenBank_ID_Protein:
1518788

# Drug_Target_1_GeneCard_ID:
KLK6

# Drug_Target_1_Gene_Name:
KLK6

# Drug_Target_1_Gene_Sequence:
>735 bp
ATGAAGAAGCTGATGGTGGTGCTGAGTCTGATTGCTGCAGCCTGGGCAGAGGAGCAGAAT
AAGTTGGTGCATGGCGGACCCTGCGACAAGACATCTCACCCCTACCAAGCTGCCCTCTAC
ACCTCGGGCCACTTGCTCTGTGGTGGGGTCCTTATCCATCCACTGTGGGTCCTCACAGCT
GCCCACTGCAAAAAACCGAATCTTCAGGTCTTCCTGGGGAAGCATAACCTTCGGCAAAGG
GAGAGTTCCCAGGAGCAGAGTTCTGTTGTCCGGGCTGTGATCCACCCTGACTATGATGCC
GCCAGCCATGACCAGGACATCATGCTGTTGCGCCTGGCACGCCCAGCCAAACTCTCTGAA
CTCATCCAGCCCCTTCCCCTGGAGAGGGACTGCTCAGCCAACACCACCAGCTGCCACATC
CTGGGCTGGGGCAAGACAGCAGATGGTGATTTCCCTGACACCATCCAGTGTGCATACATC
CACCTGGTGTCCCGTGAGGAGTGTGAGCATGCCTACCCTGGCCAGATCACCCAGAACATG
TTGTGTGCTGGGGATGAGAAGTACGGGAAGGATTCCTGCCAGGGTGATTCTGGGGGTCCG
CTGGTATGTGGAGACCACCTCCGAGGCCTTGTGTCATGGGGTAACATCCCCTGTGGATCA
AAGGAGAAGCCAGGAGTCTACACCAACGTCTGCAGATACACGAACTGGATCCAAAAAACC
ATTCAGGCCAAGTGA

# Drug_Target_1_General_Function:
Involved in protease activity

# Drug_Target_1_General_References:
10610719	Yousef GM, Luo LY, Scherer SW, Sotiropoulou G, Diamandis EP: Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics. 1999 Dec 1;62(2):251-9.
8898378	Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R: A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med. 1996 Sep;2(5):624-36.
9003450	Yamashiro K, Tsuruoka N, Kodama S, Tsujimoto M, Yamamura Y, Tanaka T, Nakazato H, Yamaguchi N: Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acta. 1997 Jan 3;1350(1):11-4.
9312124	Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, Dobbins JR, Wyrick T, Miller JR, MacKellar W, Hepburn D, Corvalan J, McClure D, Liu X, Stephenson D, Clemens J, Johnstone EM: Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem. 1997 Oct 3;272(40):25135-42.

# Drug_Target_1_HGNC_ID:
HGNC:6367

# Drug_Target_1_HPRD_ID:
04037

# Drug_Target_1_ID:
2889

# Drug_Target_1_Locus:
19q13.3

# Drug_Target_1_Molecular_Weight:
26856

# Drug_Target_1_Name:
Kallikrein-6

# Drug_Target_1_Number_of_Residues:
244

# Drug_Target_1_PDB_ID:
1L2E

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_1_Protein_Sequence:
>Kallikrein-6 precursor
MKKLMVVLSLIAAAWAEEQNKLVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTA
AHCKKPNLQVFLGKHNLRQRESSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSE
LIQPLPLERDCSANTTSCHILGWGKTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNM
LCAGDEKYGKDSCQGDSGGPLVCGDHLRGLVSWGNIPCGSKEKPGVYTNVCRYTNWIQKT
IQAK

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-16

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q92876

# Drug_Target_1_SwissProt_Name:
KLK6_HUMAN

# Drug_Target_1_Synonyms:
EC 3.4.21.-
Kallikrein-6 precursor
Neurosin
Protease M
SP59
Serine protease 18
Serine protease 9
Zyme

# Drug_Target_1_Theoretical_pI:
7.48

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
PRSS2

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
7039

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Trypsin-2

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P07478

# Drug_Target_2_SwissProt_Name:
TRY2_HUMAN

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

# Drug_Target_3_Cellular_Location:
Secreted protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
PRSS3

# Drug_Target_3_GenBank_ID_Gene:
X72781

# Drug_Target_3_GenBank_ID_Protein:
6066378

# Drug_Target_3_GeneCard_ID:
PRSS3

# Drug_Target_3_Gene_Name:
PRSS3

# Drug_Target_3_Gene_Sequence:
>787 bp
GGGCCTGGAGCTGCACCCGCTTCTGGGTGGACGCACTTGGCGAGCGGCGCGGGATGCAGA
CGGCTGCGAGGCGCTGGGCACAGTTGCTGTCCCCTTTGACGATGATGACAAGATTGTTGG
GGGCTACACCTGTGAGGAGAATTCTCTCCCCTACCAGGTGTCCCTGAATTCTGGCTCCCA
CTTCTGCGGTGGCTCCCTCATCAGCGAACAGTGGGTGGTATCAGCAGCTCACTGCTACAA
GACCCGCATCCAGGTGAGACTGGGAGAGCACAACATCAAAGTCCTGGAGGGGAATGAGCA
GTTCATCAATGCGGCCAAGATCATCCGCCACCCTAAATACAACAGGGACACTCTGGACAA
TGACATCATGCTGATCAAACTCTCCTCACCTGCCGTCATCAATGCCCGCGTGTCCACCAT
CTCTCTGCCCACCGCCCCTCCAGCTGCTGGCACTGAGTGCCTCATCTCCGGCTGGGGCAA
CACTCTGAGCTTTGGTGCTGACTACCCAGACGAGCTGAAGTGCCTGGATGCTCCGGTGCT
GACCCAGGCTGAGTGTAAAGCCTCCTACCCTGGAAAGATTACCAACAGCATGTTCTGTGT
GGGCTTCCTTGAGGGAGGCAAGGATTCCTGCCAGCGTGACTCTGGTGGCCCTGTGGTCTG
CAACGGACAGCTCCAAGGAGTTGTCTCCTGGGGCCATGGCTGTGCCTGGAAGAACAGGCC
TGGAGTCTACACCAAGGTCTACAACTATGTGGACTGGATTAAGGACACCATCGCTGCCAA
CAGCTAA

# Drug_Target_3_General_Function:
Involved in protease activity

# Drug_Target_3_General_References:
11827488	Katona G, Berglund GI, Hajdu J, Graf L, Szilagyi L: Crystal structure reveals basis for the inhibitor resistance of human brain trypsin. J Mol Biol. 2002 Feb 1;315(5):1209-18.
2326201	Tani T, Kawashima I, Mita K, Takiguchi Y: Nucleotide sequence of the human pancreatic trypsinogen III cDNA. Nucleic Acids Res. 1990 Mar 25;18(6):1631.
8294000	Wiegand U, Corbach S, Minn A, Kang J, Muller-Hill B: Cloning of the cDNA encoding human brain trypsinogen and characterization of its product. Gene. 1993 Dec 22;136(1-2):167-75.

# Drug_Target_3_HGNC_ID:
HGNC:9486

# Drug_Target_3_HPRD_ID:
06685

# Drug_Target_3_ID:
2886

# Drug_Target_3_Locus:
9p11.2

# Drug_Target_3_Molecular_Weight:
32499

# Drug_Target_3_Name:
Trypsin-3

# Drug_Target_3_Number_of_Residues:
304

# Drug_Target_3_PDB_ID:
1H4W

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_3_Protein_Sequence:
>Trypsin-3 precursor
MCGPDDRCPARWPGPGRAVKCGKGLAAARPGRVERGGAQRGGAGLELHPLLGGRTWRAAR
DADGCEALGTVAVPFDDDDKIVGGYTCEENSLPYQVSLNSGSHFCGGSLISEQWVVSAAH
CYKTRIQVRLGEHNIKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARV
STISLPTAPPAAGTECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSM
FCVGFLEGGKDSCQRDSGGPVVCNGQLQGVVSWGHGCAWKNRPGVYTKVYNYVDWIKDTI
AANS

# Drug_Target_3_Reaction:
Preferential cleavage: Arg!, Lys! INHIBITOR Tos-Lys-CH2Cl; Tos-Arg-CH2Cl

# Drug_Target_3_Signals:
Not Available

# Drug_Target_3_Specific_Function:
Preferential cleavage:Arg-|-Xaa, Lys-|-Xaa

# Drug_Target_3_SwissProt_ID:
P35030

# Drug_Target_3_SwissProt_Name:
TRY3_HUMAN

# Drug_Target_3_Synonyms:
Brain trypsinogen
EC 3.4.21.4
Mesotrypsinogen
Serine protease 3
Serine protease 4
Trypsin III
Trypsin IV
Trypsin-3 precursor

# Drug_Target_3_Theoretical_pI:
7.54

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
ATOX1

# Drug_Target_4_GenBank_ID_Gene:
U70660

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
ATOX1

# Drug_Target_4_Gene_Sequence:
>207 bp
ATGCCGAAGCACGAGTTCTCTGTGGACATGACCTGTGGAGGCTGTGCTGAAGCTGTCTCT
CGGGTCCTCAATAAGCTTGGAGGAGTTAAGTATGACATTGACCTGCCCAACAAGAAGGTC
TGCATTGAATCTGAGCACAGCATGGACACTCTGCTTGCAACCCTGAAGAAAACAGGAAAG
ACTGTTTCCTACCTTGGCCTTGAGTAG

# Drug_Target_4_General_Function:
Involved in metal ion binding

# Drug_Target_4_General_References:
10966647	Wernimont AK, Huffman DL, Lamb AL, O'Halloran TV, Rosenzweig AC: Structural basis for copper transfer by the metallochaperone for the Menkes/Wilson disease proteins. Nat Struct Biol. 2000 Sep;7(9):766-71.
9083055	Klomp LW, Lin SJ, Yuan DS, Klausner RD, Culotta VC, Gitlin JD: Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis. J Biol Chem. 1997 Apr 4;272(14):9221-6.

# Drug_Target_4_HGNC_ID:
HGNC:798

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
4814

# Drug_Target_4_Locus:
5q32

# Drug_Target_4_Molecular_Weight:
7402

# Drug_Target_4_Name:
Copper transport protein ATOX1

# Drug_Target_4_Number_of_Residues:
68

# Drug_Target_4_PDB_ID:
1FE0

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00403	HMA

# Drug_Target_4_Protein_Sequence:
>Copper transport protein ATOX1
MPKHEFSVDMTCGGCAEAVSRVLNKLGGVKYDIDLPNKKVCIESEHSMDTLLATLKKTGK
TVSYLGLE

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Could bind and deliver cytosolic copper to the copper ATPase proteins. May be important in cellular antioxidant defense

# Drug_Target_4_SwissProt_ID:
O00244

# Drug_Target_4_SwissProt_Name:
ATOX1_HUMAN

# Drug_Target_4_Synonyms:
Metal transport protein ATX1

# Drug_Target_4_Theoretical_pI:
7.35

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
DCI

# Drug_Target_5_GenBank_ID_Gene:
Z25820

# Drug_Target_5_GenBank_ID_Protein:
472987

# Drug_Target_5_GeneCard_ID:
DCI

# Drug_Target_5_Gene_Name:
DCI

# Drug_Target_5_Gene_Sequence:
>909 bp
ATGGCGCTGGTGGCTTCTGTGCGAGTCCCGGCGCGCGTTCTGCTCCGCGCGGGGGCCCGG
CTCCCGGGCGCGGCCCTCGGGCGGACGGAGCGGGCGGCCGGCGGCGGAGACGGCGCGCGG
CCGTTCGGGAGCCAGCGGGTGCTGGTGGAGCCGGACGCGGCCGCAGGGGTCGCTGTGATG
AAATTCAAGAACCCCCCAGTGAACAGCCTGAGCCTGGAGTTTCTGACGGAGCTGGTCATC
AGCCTGGAGAAGCTGGAGAATGACAAGAGCTTCCGCGGTGTCATTCTGACCTCGGACCGC
CCGGGTGTCTTCTCGGCCGGCCTGGACCTGACGGAGATGTGTGGGAGGAGCCCCGCCCAC
TACGCTGGGTACTGGAAGGCCGTTCAGGAGCTGTGGCTGCGGTTGTACCAGTCCAACCTG
GTGCTGGTCTCCGCCATCAACGGAGCCTGCCCCGCTGGAGGCTGCCTGGTGGCCCTGACC
TGTGACTACCGCATCCTGGCGGACAACCCCAGGTACTGCATAGGACTCAATGAGACCCAG
CTGGGCATCATCGCCCCTTTCTGGTTGAAAGACACCCTGGAGAACACCATCGGGCACCGG
GCGGCGGAGCGTGCCCTGCAGCTGGGGCTGCTCTTCCCGCCGGCGGAGGCCCTGCAGGTG
GGCATAGTGGACCAGGTGGTCCCGGAGGAGCAGGTGCAGAGCACTGCGCTGTCAGCGATA
GCCCAGTGGATGGCCATTCCAGACCATGCTCGACAGCTGACCAAGGCCATGATGCGAAAG
GCCACGGCCAGCCGCCTGGTCACGCAGCGCGATGCGGACGTGCAGAACTTCGTCAGCTTC
ATCTCCAAAGACTCCATCCAGAAGTCCCTGCAGATGTACTTAGAGAGGCTCAAAGAAGAA
AAAGGCTAA

# Drug_Target_5_General_Function:
Lipid transport and metabolism

# Drug_Target_5_General_References:
7829074	Janssen U, Fink T, Lichter P, Stoffel W: Human mitochondrial 3,2-trans-enoyl-CoA isomerase (DCI): gene structure and localization to chromosome 16p13.3. Genomics. 1994 Sep 1;23(1):223-8.
8198519	Kilponen JM, Hayrinen HM, Rehn M, Hiltunen JK: cDNA cloning and amino acid sequence of human mitochondrial delta 3 delta 2-enoyl-CoA isomerase: comparison of the human enzyme with its rat counterpart, mitochondrial short-chain isomerase. Biochem J. 1994 May 15;300 ( Pt 1):1-5.

# Drug_Target_5_HGNC_ID:
HGNC:2703

# Drug_Target_5_HPRD_ID:
02628

# Drug_Target_5_ID:
3211

# Drug_Target_5_Locus:
16p13.3

# Drug_Target_5_Molecular_Weight:
32816

# Drug_Target_5_Name:
3,2-trans-enoyl-CoA isomerase, mitochondrial

# Drug_Target_5_Number_of_Residues:
302

# Drug_Target_5_PDB_ID:
1SG4

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00378	ECH

# Drug_Target_5_Protein_Sequence:
>3,2-trans-enoyl-CoA isomerase, mitochondrial precursor
MALVASVRVPARVLLRAGARLPGAALGRTERAAGGGDGARRFGSQRVLVEPDAGAGVAVM
KFKNPPVNSLSLEFLTELVISLEKLENDKSFRGVILTSDRPGVFSAGLDLTEMCGRSPAH
YAGYWKAVQELWLRLYQSNLVLVSAINGACPAGGCLVALTCDYRILADNPRYCIGLNETQ
LGIIAPFWLKDTLENTIGHRAAERALQLGLLFPPAEALQVGIVDQVVPEEQVQSTALSAI
AQWMAIPDHARQLTKAMMRKATASRLVTQRDADVQNFVSFISKDSIQKSLQMYLERLKEE
KG

# Drug_Target_5_Reaction:
(3Z)-dodec-3-enoyl-CoA = (2E)-dodec-2-enoyl-CoA

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Able to isomerize both 3-cis and 3-trans double bonds into the 2-trans form in a range of enoyl-CoA species

# Drug_Target_5_SwissProt_ID:
P42126

# Drug_Target_5_SwissProt_Name:
D3D2_HUMAN

# Drug_Target_5_Synonyms:
3,2-trans-enoyl-CoA isomerase, mitochondrial precursor
D3,D2-enoyl-CoA isomerase
Delta(3),Delta(2)-enoyl-CoA isomerase
Dodecenoyl-CoA isomerase
EC 5.3.3.8

# Drug_Target_5_Theoretical_pI:
8.72

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasmic

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
M64471

# Drug_Target_6_GenBank_ID_Protein:
409446

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
sprT

# Drug_Target_6_Gene_Sequence:
>1059 bp
GTGTCCGGCGCTCCCCCGCGGCGGCGGTCCCGCACGGCGTACGTGACACGACCGCTCCCA
GCCGTACGGGGTCGTTCCGGGCGGCGCGTCCCCGGTCCGCGTGACCCGGGCGGTCCTGGA
GGGGCGGTGGTGGCGCGTACGAGCTTGGCCGAAATGTGCGCCTTGTGGCAGCGGCCACCC
GTTCGTCGACAATCGCAGCATCTTGACGGGTGCATGACCATGCCGTCGCGCCCCGTCGGG
GTTCCCACAGCGACCCCCCACGAAAGAAGGCAATCCGTGAAGCACTTCCTGCGTGCGCTG
AAGAGATGCTCCGTCGCCGTCGCCACCGTCGCCATCGCGAGTCGTCGGCCTCCAGCCCGT
CACCGGCCTCGGCCGCCCCCAACCCGCGTCGTCGGCGGAACCCGCGCGGCCCAGGGCGAG
TTCCCCTTCATGGTCCGGCTCTCCATGGGCTGCGGCGGCGCCCTCTACGCCCAGGACATC
GTCCTCACCGCGGCCCACTGCGTGAGCGGATCGGGCAACAACACCTCGATCACGGCCACC
GGCGGCGTCGTCGACCTCCAGTCGTCCAGCGCCGTCAAGGTCCGCTCCACCAAGGTCCTC
CAGGCCCCCGGCTACAACGGCACCGGCAAGGACTGGGCGCTCATCAAGCTCGCCCAGCCC
ATCAACCAGCCCACGCTGAAGATCGCCACCACCACCGCCTACAACCAGGGCACGTTCACC
GTCGCCGGCTGGGGCGCCAACCGCGAGGGCGGCAGCCAGCAGCGCTACCTGCTCAAGGCC
AACGTCCCGTTCGTCTCCGACGCCGCCTGCCGCTCCGCGTACGGCAACGAGCTCGTGGCC
AACGAGGAGATCTGCGCCGGATACCCCGACACCGGTGGCGTCGACACCTGCCAGGGTGAC
TCCGGCGGCCCGATGTTCCGCAAGGACAACGCCGACGAGTGGATCCAGGTCGGCATCGTC
AGCTGGGGCTACGGCTGCGCCCGGCCCGGCTACCCGGGTGTCTACACCGAGGTCTCGACC
TTCGCTTCCGCCATCGCCTCGGCCGCCCGCACGCTCTGA

# Drug_Target_6_General_Function:
Involved in protease activity

# Drug_Target_6_General_References:
1755852	Kim JC, Cha SH, Jeong ST, Oh SK, Byun SM: Molecular cloning and nucleotide sequence of Streptomyces griseus trypsin gene. Biochem Biophys Res Commun. 1991 Dec 16;181(2):707-13.
3135412	Read RJ, James MN: Refined crystal structure of Streptomyces griseus trypsin at 1.7 A resolution. J Mol Biol. 1988 Apr 5;200(3):523-51.
804314	Olafson RW, Jurasek L, Carpenter MR, Smillie LB: Amino acid sequence of Streptomyces griseus trypsin. Cyanogen bromide fragments and complete sequence. Biochemistry. 1975 Mar 25;14(6):1168-77.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
2947

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
26776

# Drug_Target_6_Name:
Trypsin

# Drug_Target_6_Number_of_Residues:
259

# Drug_Target_6_PDB_ID:
1OS8

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_6_Protein_Sequence:
>Trypsin precursor
MKHFLRALKRCSVAVATVAIAVVGLQPVTASAAPNPVVGGTRAAQGEFPFMVRLSMGCGG
ALYAQDIVLTAAHCVSGSGNNTSITATGGVVDLQSSSAVKVRSTKVLQAPGYNGTGKDWA
LIKLAQPINQPTLKIATTTAYNQGTFTVAGWGANREGGSQQRYLLKANVPFVSDAACRSA
YGNELVANEEICAGYPDTGGVDTCQGDSGGPMFRKDNADEWIQVGIVSWGYGCARPGYPG
VYTEVSTFASAIASAARTL

# Drug_Target_6_Reaction:
Preferential cleavage: Arg!, Lys! INHIBITOR Tos-Lys-CH2Cl; Tos-Arg-CH2Cl

# Drug_Target_6_Signals:
1-32

# Drug_Target_6_Specific_Function:
Preferential cleavage:Arg-|-Xaa, Lys-|-Xaa

# Drug_Target_6_SwissProt_ID:
P00775

# Drug_Target_6_SwissProt_Name:
TRYP_STRGR

# Drug_Target_6_Synonyms:
EC 3.4.21.4
SGT
Trypsin precursor

# Drug_Target_6_Theoretical_pI:
8.46

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Membrane
single-pass type II membrane protein (Probable)

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
ST14

# Drug_Target_7_GenBank_ID_Gene:
AF118224

# Drug_Target_7_GenBank_ID_Protein:
6647302

# Drug_Target_7_GeneCard_ID:
ST14

# Drug_Target_7_Gene_Name:
ST14

# Drug_Target_7_Gene_Sequence:
>2568 bp
ATGGGGAGCGATCGGGCCCGCAAGGGCGGAGGGGGCCCGAAGGACTTCGGCGCGGGACTC
AAGTACAACTCCCGGCACGAGAAAGTGAATGGCTTGGAGGAAGGCGTGGAGTTCCTGCCA
GTCAACAACGTCAAGAAGGTGGAAAAGCATGGCCCGGGGCGCTGGGTGGTGCTGGCAGCC
GTGCTGATCGGCCTCCTCTTGGTCTTGCTGGGGATCGGCTTCCTGGTGTGGCATTTGCAG
TACCGGGACGTGCGTGTCCAGAAGGTCTTCAATGGCTACATGAGGATCACAAATGAGAAT
TTTGTGGATGCCTACGAGAACTCCAACTCCACTGAGTTTGTAAGCCTGGCCAGCAAGGTG
AAGGACGCGCTGAAGCTGCTGTACAGCGGAGTCCCATTCCTGGGCCCCTACCACAAGGAG
TCGGCTGTGACGGCCTTCAGCGAGGGCAGCGTCATCGCCTACTACTGGTCTGAGTTCAGC
ATCCCGCAGCACCTGGTGGAGGAGGCCGAGCGCGTCATGGCCGAGGAGCGCGTAGTCATG
CTGCCCCCGCGGGCGCGCTCCCTGAAGTCCTTTGTGGTCACCTCAGTGGTGGCTTTCCCC
ACGGACTCCAAAACAGTACAGAGGACCCAGGACAACAGCTGCAGCTTTGGCCTGCACGCC
CGCGGTGTGGAGCTGATGCGCTTCACCACGCCCGGCTTCCCTGACAGCCCCTACCCCGCT
CATGCCCGCTGCCAGTGGGCCCTGCGGGGGGACGCCGACTCAGTGCTGAGCCTCACCTTC
CGCAGCTTTGACCTTGCGTCCTGCGACGAGCGCGGCAGCGACCTGGTGACGGTGTACAAC
ACCCTGAGCCCCATGGAGCCCCACGCCCTGGTGCAGTTGTGTGGCACCTACCCTCCCTCC
TACAACCTGACCTTCCACTCCTCCCAGAACGTCCTGCTCATCACACTGATAACCAACACT
GAGCGGCGGCATCCCGGCTTTGAGGCCACCTTCTTCCAGCTGCCTAGGATGAGCAGCTGT
GGAGGCCGCTTACGTAAAGCCCAGGGGACATTCAACAGCCCCTACTACCCAGGCCACTAC
CCACCCAACATTGACTGCACATGGAACATTGAGGTGCCCAACAACCAGCATGTGAAGGTG
CGCTTCAAATTCTTCTACCTGCTGGAGCCCGGCGTGCCTGCGGGCACCTGCCCCAAGGAC
TACGTGGAGATCAATGGGGAGAAATACTGCGGAGAGAGGTCCCAGTTCGTCGTCACCAGC
AACAGCAACAAGATCACAGTTCGCTTCCACTCAGATCAGTCCTACACCGACACCGGCTTC
TTAGCTGAATACCTCTCCTACGACTCCAGTGACCCATGCCCGGGGCAGTTCACGTGCCGC
ACGGGGCGGTGTATCCGGAAGGAGCTGCGCTGTGATGGCTGGGCCGACTGCACCGACCAC
AGCGATGAGCTCAACTGCAGTTGCGACGCCGGCCACCAGTTCACGTGCAAGAACAAGTTC
TGCAAGCCCCTCTTCTGGGTCTGCGACAGTGTGAACGACTGCGGAGACAACAGCGACGAG
CAGGGGTGCAGTTGTCCGGCCCAGACCTTCAGGTGTTCCAATGGGAAGTGCCTCTCGAAA
AGCCAGCAGTGCAATGGGAAGGACGACTGTGGGGACGGGTCCGACGAGGCCTCCTGCCCC
AAGGTGAACGTCGTCACTTGTACCAAACACACCTACCGCTGCCTCAATGGGCTCTGCTTG
AGCAAGGGCAACCCTGAGTGTGACGGGAAGGAGGACTGTAGCGACGGCTCAGATGAGAAG
GACTGCGACTGTGGGCTGCGGTCATTCACGAGACAGGCTCGTGTTGTTGGGGGCACGGAT
GCGGATGAGGGCGAGTGGCCCTGGCAGGTAAGCCTGCATGCTCTGGGCCAGGGCCACATC
TGCGGTGCTTCCCTCATCTCTCCCAACTGGCTGGTCTCTGCCGCACACTGCTACATCGAT
GACAGAGGATTCAGGTACTCAGACCCCACGCAGTGGACGGCCTTCCTGGGCTTGCACGAC
CAGAGCCAGCGCAGCGCCCCTGGGGTGCAGGAGCGCAGGCTCAAGCGCATCATCTCCCAC
CCCTTCTTCAATGACTTCACCTTCGACTATGACATCGCGCTGCTGGAGCTGGAGAAACCG
GCAGAGTACAGCTCCATGGTGCGGCCCATCTGCCTGCCGGACGCCTCCCATGTCTTCCCT
GCCGGCAAGGCCATCTGGGTCACGGGCTGGGGACACACCCAGTATGGAGGCACTGGCGCG
CTGATCCTGCAAAAGGGTGAGATCCGCGTCATCAACCAGACCACCTGCGAGAACCTCCTG
CCGCAGCAGATCACGCCGCGCATGATGTGCGTGGGCTTCCTCAGCGGCGGCGTGGACTCC
TGCCAGGGTGATTCCGGGGGACCCCTGTCCAGCGTGGAGGCGGATGGGCGGATCTTCCAG
GCCGGTGTGGTGAGCTGGGGAGACGGCTGCGCTCAGAGGAACAAGCCAGGCGTGTACACA
AGGCTCCCTCTGTTTCGGGACTGGATCAAAGAGAACACTGGGGTATAG

# Drug_Target_7_General_Function:
Involved in protease activity

# Drug_Target_7_General_References:
10373424	Lin CY, Anders J, Johnson M, Sang QA, Dickson RB: Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem. 1999 Jun 25;274(26):18231-6.
10373425	Lin CY, Anders J, Johnson M, Dickson RB: Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem. 1999 Jun 25;274(26):18237-42.
10500122	Takeuchi T, Shuman MA, Craik CS: Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11054-61.

# Drug_Target_7_HGNC_ID:
HGNC:11344

# Drug_Target_7_HPRD_ID:
06005

# Drug_Target_7_ID:
3011

# Drug_Target_7_Locus:
11q24-q25

# Drug_Target_7_Molecular_Weight:
94770

# Drug_Target_7_Name:
Suppressor of tumorigenicity protein 14

# Drug_Target_7_Number_of_Residues:
855

# Drug_Target_7_PDB_ID:
1EAX

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00057	Ldl_recept_a
PF00089	Trypsin
PF00431	CUB
PF01390	SEA

# Drug_Target_7_Protein_Sequence:
>Suppressor of tumorigenicity protein 14
MGSDRARKGGGGPKDFGAGLKYNSRHEKVNGLEEGVEFLPVNNVKKVEKHGPGRWVVLAA
VLIGLLLVLLGIGFLVWHLQYRDVRVQKVFNGYMRITNENFVDAYENSNSTEFVSLASKV
KDALKLLYSGVPFLGPYHKESAVTAFSEGSVIAYYWSEFSIPQHLVEEAERVMAEERVVM
LPPRARSLKSFVVTSVVAFPTDSKTVQRTQDNSCSFGLHARGVELMRFTTPGFPDSPYPA
HARCQWALRGDADSVLSLTFRSFDLASCDERGSDLVTVYNTLSPMEPHALVQLCGTYPPS
YNLTFHSSQNVLLITLITNTERRHPGFEATFFQLPRMSSCGGRLRKAQGTFNSPYYPGHY
PPNIDCTWNIEVPNNQHVKVRFKFFYLLEPGVPAGTCPKDYVEINGEKYCGERSQFVVTS
NSNKITVRFHSDQSYTDTGFLAEYLSYDSSDPCPGQFTCRTGRCIRKELRCDGWADCTDH
SDELNCSCDAGHQFTCKNKFCKPLFWVCDSVNDCGDNSDEQGCSCPAQTFRCSNGKCLSK
SQQCNGKDDCGDGSDEASCPKVNVVTCTKHTYRCLNGLCLSKGNPECDGKEDCSDGSDEK
DCDCGLRSFTRQARVVGGTDADEGEWPWQVSLHALGQGHICGASLISPNWLVSAAHCYID
DRGFRYSDPTQWTAFLGLHDQSQRSAPGVQERRLKRIISHPFFNDFTFDYDIALLELEKP
AEYSSMVRPICLPDASHVFPAGKAIWVTGWGHTQYGGTGALILQKGEIRVINQTTCENLL
PQQITPRMMCVGFLSGGVDSCQGDSGGPLSSVEADGRIFQAGVVSWGDGCAQRNKPGVYT
RLPLFRDWIKENTGV

# Drug_Target_7_Reaction:
Cleaves various synthetic substrates with Arg or Lys at the P1 position and prefers small side-chain amino acids, such as Ala and Gly, at the P2 position

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site

# Drug_Target_7_SwissProt_ID:
Q9Y5Y6

# Drug_Target_7_SwissProt_Name:
ST14_HUMAN

# Drug_Target_7_Synonyms:
EC 3.4.21.109
MT-SP1
Matriptase
Membrane-type serine protease 1
Prostamin
Serine protease 14
Serine protease TADG-15
Tumor-associated differentially-expressed gene 15 protein

# Drug_Target_7_Theoretical_pI:
6.53

# Drug_Target_7_Transmembrane_Regions:
56-76

# Drug_Target_8_Cellular_Location:
Secreted protein

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
PLAU

# Drug_Target_8_GenBank_ID_Gene:
X02419

# Drug_Target_8_GenBank_ID_Protein:
1834524

# Drug_Target_8_GeneCard_ID:
PLAU

# Drug_Target_8_Gene_Name:
PLAU

# Drug_Target_8_Gene_Sequence:
>1296 bp
ATGAGAGCCCTGCTGGCGCGCCTGCTTCTCTGCGTCCTGGTCGTGAGCGACTCCAAAGGC
AGCAATGAACTTCATCAAGTTCCATCGAACTGTGACTGTCTAAATGGAGGAACATGTGTG
TCCAACAAGTACTTCTCCAACATTCACTGGTGCAACTGCCCAAAGAAATTCGGAGGGCAG
CACTGTGAAATAGATAAGTCAAAAACCTGCTATGAGGGGAATGGTCACTTTTACCGAGGA
AAGGCCAGCACTGACACCATGGGCCGGCCCTGCCTGCCCTGGAACTCTGCCACTGTCCTT
CAGCAAACGTACCATGCCCACAGATCTGATGCTCTTCAGCTGGGCCTGGGGAAACATAAT
TACTGCAGGAACCCAGACAACCGGAGGCGACCCTGGTGCTATGTGCAGGTGGGCCTAAAG
CCGCTTGTCCAAGAGTGCATGGTGCATGACTGCGCAGATGGAAAAAAGCCCTCCTCTCCT
CCAGAAGAATTAAAATTTCAGTGTGGCCAAAAGACTCTGAGGCCCCGCTTTAAGATTATT
GGGGGAGAATTCACCACCATCGAGAACCAGCCCTGGTTTGCGGCCATCTACAGGAGGCAC
CGGGGGGGCTCTGTCACCTACGTGTGTGGAGGCAGCCTCATGAGCCCTTGCTGGGTGATC
AGCGCCACACACTGCTTCATTGATTACCCAAAGAAGGAGGACTACATCGTCTACCTGGGT
CGCTCAAGGCTTAACTCCAACACGCAAGGGGAGATGAAGTTTGAGGTGGAAAACCTCATC
CTACACAAGGACTACAGCGCTGACACGCTTGCTCACCACAACGACATTGCCTTGCTGAAG
ATCCGTTCCAAGGAGGGCAGGTGTGCGCAGCCATCCCGGACTATACAGACCATCTGCCTG
CCCTCGATGTATAACGATCCCCAGTTTGGCACAAGCTGTGAGATCACTGGCTTTGGAAAA
GAGAATTCTACCGACTATCTCTATCCGGAGCAGCTGAAAATGACTGTTGTGAAGCTGATT
TCCCACCGGGAGTGTCAGCAGCCCCACTACTACGGCTCTGAAGTCACCACCAAAATGCTG
TGTGCTGCTGACCCACAGTGGAAAACAGATTCCTGCCAGGGAGACTCAGGGGGACCCCTC
GTCTGTTCCCTCCAAGGCCGCATGACTTTGACTGGAATTGTGAGCTGGGGCCGTGGATGT
GCCCTGAAGGACAAGCCAGGCGTCTACACGAGAGTCTCACACTTCTTACCCTGGATCCGC
AGTCACACCAAGGAAGAGAATGGCCTGGCCCTCTGA

# Drug_Target_8_General_Function:
Involved in chemotaxis and signal transduction activity

# Drug_Target_8_General_References:
10636902	Behrendt N, Jensen ON, Engelholm LH, Mortz E, Mann M, Dano K: A urokinase receptor-associated protein with specific collagen binding properties. J Biol Chem. 2000 Jan 21;275(3):1993-2002.
10805774	Sperl S, Jacob U, Arroyo de Prada N, Sturzebecher J, Wilhelm OG, Bode W, Magdolen V, Huber R, Moroder L: (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5113-8.
11384978	Liu CX, Li Y, Obermoeller-McCormick LM, Schwartz AL, Bu G: The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. J Biol Chem. 2001 Aug 3;276(31):28889-96. Epub 2001 May 30.
1327118	Li X, Smith RA, Dobson CM: Sequential 1H NMR assignments and secondary structure of the kringle domain from urokinase. Biochemistry. 1992 Oct 13;31(40):9562-71.
2415429	Nagai M, Hiramatsu R, Kaneda T, Hayasuke N, Arimura H, Nishida M, Suyama T: Molecular cloning of cDNA coding for human preprourokinase. Gene. 1985;36(1-2):183-8.
2536903	Oswald RE, Bogusky MJ, Bamberger M, Smith RA, Dobson CM: Dynamics of the multidomain fibrinolytic protein urokinase from two-dimensional NMR. Nature. 1989 Feb 9;337(6207):579-82.
2987867	Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F: The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res. 1985 Apr 25;13(8):2759-71.
3888571	Jacobs P, Cravador A, Loriau R, Brockly F, Colau B, Chuchana P, van Elsen A, Herzog A, Bollen A: Molecular cloning, sequencing, and expression in Escherichia coli of human preprourokinase cDNA. DNA. 1985 Apr;4(2):139-46.
6589620	Verde P, Stoppelli MP, Galeffi P, Di Nocera P, Blasi F: Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4727-31.
6749491	Schaller J, Nick H, Rickli EE, Gillessen D, Lergier W, Studer RO: Human low-molecular-weight urinary urokinase. Partial characterization and preliminary sequence data of the two polypeptide chains. Eur J Biochem. 1982 Jul;125(2):251-7.
6754569	Gunzler WA, Steffens GJ, Otting F, Kim SM, Frankus E, Flohe L: The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe Seylers Z Physiol Chem. 1982 Oct;363(10):1155-65.
6754572	Steffens GJ, Gunzler WA, Otting F, Frankus E, Flohe L: The complete amino acid sequence of low molecular mass urokinase from human urine. Hoppe Seylers Z Physiol Chem. 1982 Sep;363(9):1043-58.
8107091	Li X, Bokman AM, Llinas M, Smith RA, Dobson CM: Solution structure of the kringle domain from urokinase-type plasminogen activator. J Mol Biol. 1994 Feb 4;235(5):1548-59.
8591045	Spraggon G, Phillips C, Nowak UK, Ponting CP, Saunders D, Dobson CM, Stuart DI, Jones EY: The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure. 1995 Jul 15;3(7):681-91.
8652631	Yoshimoto M, Ushiyama Y, Sakai M, Tamaki S, Hara H, Takahashi K, Sawasaki Y, Hanada K: Characterization of single chain urokinase-type plasminogen activator with a novel amino-acid substitution in the kringle structure. Biochim Biophys Acta. 1996 Mar 7;1293(1):83-9.
9065988	Conne B, Berczy M, Belin D: Detection of polymorphisms in the human urokinase-type plasminogen activator gene. Thromb Haemost. 1997 Mar;77(3):434-5.
9151681	Franco P, Iaccarino C, Chiaradonna F, Brandazza A, Iavarone C, Mastronicola MR, Nolli ML, Stoppelli MP: Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. J Cell Biol. 1997 May 5;137(3):779-91.
9194591	Turkmen B, Schmitt M, Schmalfeldt B, Trommler P, Hell W, Creutzburg S, Graeff H, Magdolen V: Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer. Electrophoresis. 1997 May;18(5):686-9.

# Drug_Target_8_HGNC_ID:
HGNC:9052

# Drug_Target_8_HPRD_ID:
01883

# Drug_Target_8_ID:
1074

# Drug_Target_8_Locus:
10q24

# Drug_Target_8_Molecular_Weight:
48526

# Drug_Target_8_Name:
Urokinase-type plasminogen activator

# Drug_Target_8_Number_of_Residues:
431

# Drug_Target_8_PDB_ID:
1VJA

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00051	Kringle
PF00089	Trypsin

# Drug_Target_8_Protein_Sequence:
>Urokinase-type plasminogen activator precursor
MRALLARLLLCVLVVSDSKGSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQ
HCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHN
YCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKII
GGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMSPCWVISATHCFIDYPKKEDYIVYLG
RSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICL
PSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKML
CAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIR
SHTKEENGLAL

# Drug_Target_8_Reaction:
Specific cleavage of Arg!Val bond in plasminogen to form plasmin

# Drug_Target_8_Signals:
1-20

# Drug_Target_8_Specific_Function:
Specifically cleave the zymogen plasminogen to form the active enzyme plasmin

# Drug_Target_8_SwissProt_ID:
P00749

# Drug_Target_8_SwissProt_Name:
UROK_HUMAN

# Drug_Target_8_Synonyms:
EC 3.4.21.73
U-plasminogen activator
Urokinase-type plasminogen activator precursor
uPA

# Drug_Target_8_Theoretical_pI:
8.48

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Secreted protein
extracellular space

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
PRSS1

# Drug_Target_9_GenBank_ID_Gene:
M22612

# Drug_Target_9_GenBank_ID_Protein:
521216

# Drug_Target_9_GeneCard_ID:
PRSS1

# Drug_Target_9_Gene_Name:
PRSS1

# Drug_Target_9_Gene_Sequence:
>744 bp
ATGAATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTTGCTGCCCCCTTTGATGAT
GATGACAAGATCGTTGGGGGCTACAACTGTGAGGAGAATTCTGTCCCCTACCAGGTGTCC
CTGAATTCTGGCTACCACTTCTGTGGTGGCTCCCTCATCAACGAACAGTGGGTGGTATCA
GCAGGCCACTGCTACAAGTCCCGCATCCAGGTGAGACTGGGAGAGCACAACATCGAAGTC
CTGGAGGGGAATGAGCAGTTCATCAATGCAGCCAAGATCATCCGCCACCCCCAATACGAC
AGGAAGACTCTGAACAATGACATCATGTTAATCAAGCTCTCCTCACGTGCAGTAATCAAC
GCCCGCGTGTCCACCATCTCTCTGCCCACCGCCCCTCCAGCCACTGGCACGAAGTGCCTC
ATCTCTGGCTGGGGCAACACTGCGAGCTCTGGCGCCGACTACCCAGACGAGCTGCAGTGC
CTGGATGCTCCTGTGCTGAGCCAGGCTAAGTGTGAAGCCTCCTACCCTGGAAAGATTACC
AGCAACATGTTCTGTGTGGGCTTCCTTGAGGGAGGCAAGGATTCATGTCAGGGTGATTCT
GGTGGCCCTGTGGTCTGCAATGGACAGCTCCAAGGAGTTGTCTCCTGGGGTGATGGCTGT
GCCCAGAAGAACAAGCCTGGAGTCTACACCAAGGTCTACAACTACGTGAAATGGATTAAG
AACACCATAGCTGCCAATAGCTAA

# Drug_Target_9_General_Function:
Involved in protease activity

# Drug_Target_9_General_References:
10204851	Ferec C, Raguenes O, Salomon R, Roche C, Bernard JP, Guillot M, Quere I, Faure C, Mercier B, Audrezet MP, Guillausseau PJ, Dupont C, Munnich A, Bignon JD, Le Bodic L: Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis. J Med Genet. 1999 Mar;36(3):228-32.
10381903	Witt H, Luck W, Becker M: A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology. 1999 Jul;117(1):7-10.
10930381	Teich N, Ockenga J, Hoffmeister A, Manns M, Mossner J, Keim V: Chronic pancreatitis associated with an activation peptide mutation that facilitates trypsin activation. Gastroenterology. 2000 Aug;119(2):461-5.
11788572	Pfutzer R, Myers E, Applebaum-Shapiro S, Finch R, Ellis I, Neoptolemos J, Kant JA, Whitcomb DC: Novel cationic trypsinogen (PRSS1) N29T and R122C mutations cause autosomal dominant hereditary pancreatitis. Gut. 2002 Feb;50(2):271-2.
2598466	Kimland M, Russick C, Marks WH, Borgstrom A: Immunoreactive anionic and cationic trypsin in human serum. Clin Chim Acta. 1989 Sep 15;184(1):31-46.
3011602	Emi M, Nakamura Y, Ogawa M, Yamamoto T, Nishide T, Mori T, Matsubara K: Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene. 1986;41(2-3):305-10.
8683601	Gaboriaud C, Serre L, Guy-Crotte O, Forest E, Fontecilla-Camps JC: Crystal structure of human trypsin 1: unexpected phosphorylation of Tyr151. J Mol Biol. 1996 Jun 28;259(5):995-1010.
8841182	Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, Martin SP, Gates LK Jr, Amann ST, Toskes PP, Liddle R, McGrath K, Uomo G, Post JC, Ehrlich GD: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996 Oct;14(2):141-5.
9322498	Gorry MC, Gabbaizedeh D, Furey W, Gates LK Jr, Preston RA, Aston CE, Zhang Y, Ulrich C, Ehrlich GD, Whitcomb DC: Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology. 1997 Oct;113(4):1063-8.
9633818	Teich N, Mossner J, Keim V: Mutations of the cationic trypsinogen in hereditary pancreatitis. Hum Mutat. 1998;12(1):39-43.

# Drug_Target_9_HGNC_ID:
HGNC:9475

# Drug_Target_9_HPRD_ID:
02039

# Drug_Target_9_ID:
3176

# Drug_Target_9_Locus:
7q32-qter|7q34

# Drug_Target_9_Molecular_Weight:
26558

# Drug_Target_9_Name:
Trypsin-1

# Drug_Target_9_Number_of_Residues:
247

# Drug_Target_9_PDB_ID:
1TRN

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_9_Protein_Sequence:
>Trypsin-1 precursor
MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVS
AGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVIN
ARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKIT
SNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIK
NTIAANS

# Drug_Target_9_Reaction:
Preferential cleavage: Arg!, Lys! INHIBITOR Tos-Lys-CH2Cl; Tos-Arg-CH2Cl

# Drug_Target_9_Signals:
1-15

# Drug_Target_9_Specific_Function:
Preferential cleavage:Arg-|-Xaa, Lys-|-Xaa

# Drug_Target_9_SwissProt_ID:
P07477

# Drug_Target_9_SwissProt_Name:
TRY1_HUMAN

# Drug_Target_9_Synonyms:
Cationic trypsinogen
EC 3.4.21.4
Serine protease 1
Trypsin I
Trypsin-1 precursor

# Drug_Target_9_Theoretical_pI:
6.48

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB03127
